Literature DB >> 12679445

Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.

Mara J Horwitz1, Mary Beth Tedesco, Susan M Sereika, Bruce W Hollis, Adolfo Garcia-Ocaña, Andrew F Stewart.   

Abstract

PTH and PTH-related protein (PTHrP) cause primary hyperparathyroidism and humoral hypercalcemia of malignancy (HHM), respectively. These syndromes are similar in several important ways, but differ in several characteristic, yet unexplained, ways. Two of the unresolved questions in HHM and hyperparathyroidism involve renal physiology. 1) Why does renal proximal tubular production of 1,25-dihydroxyvitamin D [1,25-(OH)(2)D] differ between the two syndromes? 2) Do distal tubular calcium responses to PTH and PTHrP differ in the two syndromes? To address these questions, we compared the two peptides, human PTH-(1-34) and PTHrP-(1-36), in a direct, head to head study using a continuous, steady state infusion of each peptide at the same dose in normal human volunteers for 46 h. We had previously described such methods as applied to PTHrP, but a direct multiday comparison of PTHrP to PTH has not previously been reported. In two groups (seven subjects each) of healthy young (25- to 35-yr-old) normal volunteers, PTH and PTHrP infused at 8 pmol/kg.h displayed similar calcemic effects, although PTH was slightly more potent in this regard. Both peptides also displayed similar phosphaturic effects. In addition, both peptides had similar effects on renal tubular calcium handling, yielding fractional calcium excretion values of approximately 3.5%, some 50% below the values (6.5%) observed in subjects rendered similarly hypercalcemic by the infusion of calcium. In contrast to these several quantitatively similar effects of PTH and PTHrP, PTH tended to be selectively more effective than PTHrP in stimulating renal production of 1,25-(OH)(2)D. These studies indicate that renal tubular calcium reabsorption is likely to contribute to hypercalcemia in patients with HHM. In addition, PTH may be selectively more effective than PTHrP in stimulating 1,25-(OH)(2)D production, in contrast to its phosphaturic, calcemic effects and its effects to stimulate nephrogenous cAMP excretion and renal tubular calcium reabsorption.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679445     DOI: 10.1210/jc.2002-020773

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Adolfo Garcia-Ocaña; Alessandro Bisello; Bruce W Hollis; Caren Gundberg; Andrew F Stewart
Journal:  Osteoporos Int       Date:  2005-09-07       Impact factor: 4.507

2.  Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: Pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels.

Authors:  A Benit; J Allard; J Rimailho; J Fauvel; G Escourrou; D Vezzosi; F Donadille; A Bennet; P Caron
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

3.  Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation.

Authors:  Makoto Okazaki; Sebastien Ferrandon; Jean-Pierre Vilardaga; Mary L Bouxsein; John T Potts; Thomas J Gardella
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-22       Impact factor: 11.205

4.  Increased PTHrP and decreased estrogens alter bone turnover but do not reproduce the full effects of lactation on the skeleton.

Authors:  Laleh Ardeshirpour; Susan Brian; Pamela Dann; Joshua VanHouten; John Wysolmerski
Journal:  Endocrinology       Date:  2010-11-03       Impact factor: 4.736

5.  When two keys fit one lock, surprises follow.

Authors:  Michael Rosenblatt
Journal:  Nat Chem Biol       Date:  2009-10       Impact factor: 15.040

6.  A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Linda Prebehala; Caren M Gundberg; Bruce W Hollis; Alessandro Bisello; Adolfo Garcia-Ocaña; Raquel M Carneiro; Andrew F Stewart
Journal:  J Bone Miner Res       Date:  2011-09       Impact factor: 6.741

Review 7.  Abaloparatide.

Authors:  Stefano Gonnelli; Carla Caffarelli
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

8.  The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84).

Authors:  Katherine Wesseling-Perry; G Chris Harkins; He-jing Wang; Robert Elashoff; Barbara Gales; Mara J Horwitz; Andrew F Stewart; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2010-04-09       Impact factor: 5.958

9.  Hypercalcemia as Initial Presentation of Metastatic Adenocarcinoma of Gastric Origin: A Case Report and Review of the Literature.

Authors:  Mehandar Kumar; Abhishek Kumar; Vinod Kumar; Supreet Kaur; Michael Maroules
Journal:  J Gastric Cancer       Date:  2016-09-30       Impact factor: 3.720

10.  Retromer terminates the generation of cAMP by internalized PTH receptors.

Authors:  Timothy N Feinstein; Vanessa L Wehbi; Juan A Ardura; David S Wheeler; Sebastien Ferrandon; Thomas J Gardella; Jean-Pierre Vilardaga
Journal:  Nat Chem Biol       Date:  2011-03-27       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.